Skip to main content
Erschienen in: Cancer Causes & Control 5/2017

13.02.2017 | Original paper

Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles

verfasst von: Linda E. Kelemen, Peter F. Rambau, Jennifer M. Koziak, Helen Steed, Martin Köbel

Erschienen in: Cancer Causes & Control | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Synchronous endometrial and ovarian tumors (SEOs) are diagnosed in 10% of ovarian cancer patients. We examined predictors of SEOs, evaluated associations of SEOs with survival and characterized ovarian tumor profiles using immunohistochemistry.

Methods

We included patients with endometrioid (n = 180) and clear cell (n = 165) ovarian carcinoma identified from the Alberta Cancer Registry between 1979 and 2010 for whom we abstracted medical records and constructed tumor tissue microarrays (TMAs). A concurrent diagnosis of endometrial cancer was obtained from the medical chart. We used unconditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) and Cox proportional hazards models to estimate hazard ratios (HRs) and 95% CIs. Protein expression in ovarian tumors of patients with and without SEOs was evaluated using Fisher’s exact test.

Results

Comparing 52 patients with SEO tumors to 293 patients with endometrioid or clear cell ovarian carcinomas, endometriosis at the ovary (OR = 0.45, 95% CI = 0.23–0.87, p = 0.02) was the strongest predictor of decreased risk in multivariable models. Premenopausal status (OR = 2.17, 95% CI = 0.92–5.13, p = 0.08) and lower pre-treatment CA125 levels (OR = 0.17, 95% CI = 0.02–1.32, p = 0.09) showed weaker associations. There were no significant differences in survival between patients with or without SEO tumors. More patients with SEO tumors compared to endometrioid ovarian carcinoma were deficient in MLH1, PMS2 and PTEN (p ≤ 0.03).

Conclusions

Endometriosis may not be the mechanism by which SEO cancers arise. Altered tumor oncoprotein expression between women with and without SEOs indicates important biological differences although this did not translate into prognostic differences.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat American Cancer Society (2015) Cancer facts and figures 2015. Estimated new cancer cases and deaths by sex, U.S., all sites, 2015. American Cancer Society, Atlanta American Cancer Society (2015) Cancer facts and figures 2015. Estimated new cancer cases and deaths by sex, U.S., all sites, 2015. American Cancer Society, Atlanta
2.
Zurück zum Zitat Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE (2001) Simultaneously detected endometrial and ovarian carcinomas–a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol 83:355–362CrossRefPubMed Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE (2001) Simultaneously detected endometrial and ovarian carcinomas–a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol 83:355–362CrossRefPubMed
3.
Zurück zum Zitat Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO classification of tumours of female reproductive organs. IARC, Lyon Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO classification of tumours of female reproductive organs. IARC, Lyon
4.
Zurück zum Zitat Scully RE, Young RH, Clement PB (1998) Endometrioid tumors. In: Scully RE, Young RH, Clement PB (eds) Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. Third series, fascicle 23. Armed Forces Instiute of Pathology, Washington, DC, pp 107–140 Scully RE, Young RH, Clement PB (1998) Endometrioid tumors. In: Scully RE, Young RH, Clement PB (eds) Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. Third series, fascicle 23. Armed Forces Instiute of Pathology, Washington, DC, pp 107–140
5.
Zurück zum Zitat Ramus SJ, Elmasry K, Luo Z et al (2008) Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer. Clin Cancer Res 14:5840–5848CrossRefPubMed Ramus SJ, Elmasry K, Luo Z et al (2008) Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer. Clin Cancer Res 14:5840–5848CrossRefPubMed
6.
Zurück zum Zitat Heitz F, Amant F, Fotopoulou C et al (2014) Synchronous ovarian and endometrial cancer—an international multicenter case–control study. Int J Gynecol Cancer 24:54–60CrossRefPubMed Heitz F, Amant F, Fotopoulou C et al (2014) Synchronous ovarian and endometrial cancer—an international multicenter case–control study. Int J Gynecol Cancer 24:54–60CrossRefPubMed
7.
Zurück zum Zitat Tavassoulu FA, Devilee P (2003) World Health Organization classification of tumors. Pathology and genetics of tumors of the breast and female genital organs. IARC Press, Lyon Tavassoulu FA, Devilee P (2003) World Health Organization classification of tumors. Pathology and genetics of tumors of the breast and female genital organs. IARC Press, Lyon
8.
Zurück zum Zitat Mangili G, Bergamini A, Taccagni G et al (2012) Unraveling the two entities of endometrioid ovarian cancer: a single center clinical experience. Gynecol Oncol 126:403–407CrossRefPubMed Mangili G, Bergamini A, Taccagni G et al (2012) Unraveling the two entities of endometrioid ovarian cancer: a single center clinical experience. Gynecol Oncol 126:403–407CrossRefPubMed
9.
10.
Zurück zum Zitat Kelemen LE, Warren GW, Koziak JM, Kobel M, Steed H (2016) Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer. Gynecol Oncol 140:124–130CrossRefPubMed Kelemen LE, Warren GW, Koziak JM, Kobel M, Steed H (2016) Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer. Gynecol Oncol 140:124–130CrossRefPubMed
11.
Zurück zum Zitat Gilks CB, Ionescu DN, Kalloger SE et al (2008) Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39:1239–1251CrossRefPubMed Gilks CB, Ionescu DN, Kalloger SE et al (2008) Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39:1239–1251CrossRefPubMed
12.
13.
Zurück zum Zitat Rambau PF, Duggan MA, Ghatage P et al (2016) Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas. Histopathology 69:288–297CrossRefPubMed Rambau PF, Duggan MA, Ghatage P et al (2016) Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas. Histopathology 69:288–297CrossRefPubMed
14.
Zurück zum Zitat Kobel M, Piskorz AM, Lee S et al (2016) Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res 2:247–258CrossRefPubMedPubMedCentral Kobel M, Piskorz AM, Lee S et al (2016) Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res 2:247–258CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Hosmer DW, Lameshow SL (1999) Applied survival analysis: regression modeling of time to event data. Wiley, New York Hosmer DW, Lameshow SL (1999) Applied survival analysis: regression modeling of time to event data. Wiley, New York
16.
17.
Zurück zum Zitat AlHilli MM, Dowdy SC, Weaver AL et al (2012) Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case–control study. Gynecol Oncol 125:109–113CrossRefPubMed AlHilli MM, Dowdy SC, Weaver AL et al (2012) Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case–control study. Gynecol Oncol 125:109–113CrossRefPubMed
18.
Zurück zum Zitat Mogensen JB, Kjaer SK, Mellemkjaer L, Jensen A (2016) Endometriosis and risks for ovarian, endometrial and breast cancers: a nationwide cohort study. Gynecol Oncol 143:87–92CrossRefPubMed Mogensen JB, Kjaer SK, Mellemkjaer L, Jensen A (2016) Endometriosis and risks for ovarian, endometrial and breast cancers: a nationwide cohort study. Gynecol Oncol 143:87–92CrossRefPubMed
19.
Zurück zum Zitat Buis CC, van Leeuwen FE, Mooij TM, Burger CW, Group OP (2013) Increased risk for ovarian cancer and borderline ovarian tumours in subfertile women with endometriosis. Hum Reprod 28:3358–3369CrossRefPubMed Buis CC, van Leeuwen FE, Mooij TM, Burger CW, Group OP (2013) Increased risk for ovarian cancer and borderline ovarian tumours in subfertile women with endometriosis. Hum Reprod 28:3358–3369CrossRefPubMed
20.
Zurück zum Zitat Pearce CL, Templeman C, Rossing MA et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncol 13:385–394CrossRefPubMedPubMedCentral Pearce CL, Templeman C, Rossing MA et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncol 13:385–394CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Garg K, Shih K, Barakat R, Zhou Q, Iasonos A, Soslow RA (2009) Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol 33:1869–1877CrossRefPubMed Garg K, Shih K, Barakat R, Zhou Q, Iasonos A, Soslow RA (2009) Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol 33:1869–1877CrossRefPubMed
22.
Zurück zum Zitat Kobel M, Kalloger SE, Huntsman DG et al (2010) Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 29:203–211CrossRefPubMed Kobel M, Kalloger SE, Huntsman DG et al (2010) Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 29:203–211CrossRefPubMed
23.
Zurück zum Zitat Kok VC, Tsai HJ, Su CF, Lee CK (2015) The risks for ovarian, endometrial, breast, colorectal, and other cancers in women with newly diagnosed endometriosis or adenomyosis: a population-based study. Int J Gynecol Cancer 25:968–976CrossRefPubMed Kok VC, Tsai HJ, Su CF, Lee CK (2015) The risks for ovarian, endometrial, breast, colorectal, and other cancers in women with newly diagnosed endometriosis or adenomyosis: a population-based study. Int J Gynecol Cancer 25:968–976CrossRefPubMed
24.
Zurück zum Zitat Anglesio MS, Wang YK, Maassen M, et al. (2016) Synchronous endometrial and ovarian carcinomas: evidence of clonality. J Natl Cancer Inst 108: djv428CrossRefPubMed Anglesio MS, Wang YK, Maassen M, et al. (2016) Synchronous endometrial and ovarian carcinomas: evidence of clonality. J Natl Cancer Inst 108: djv428CrossRefPubMed
25.
Zurück zum Zitat Schultheis AM, Ng CK, De Filippo MR, et al. (2016) Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas. J Natl Cancer Inst 108: djv427CrossRefPubMed Schultheis AM, Ng CK, De Filippo MR, et al. (2016) Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas. J Natl Cancer Inst 108: djv427CrossRefPubMed
26.
Zurück zum Zitat Djordjevic B, Hennessy BT, Li J et al (2012) Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 25:699–708CrossRefPubMedPubMedCentral Djordjevic B, Hennessy BT, Li J et al (2012) Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 25:699–708CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Kobayashi Y, Nakamura K, Nomura H et al (2015) Clinicopathologic analysis with immunohistochemistry for DNA mismatch repair protein expression in synchronous primary endometrial and ovarian cancers. Int J Gynecol Cancer 25:440–446CrossRefPubMed Kobayashi Y, Nakamura K, Nomura H et al (2015) Clinicopathologic analysis with immunohistochemistry for DNA mismatch repair protein expression in synchronous primary endometrial and ovarian cancers. Int J Gynecol Cancer 25:440–446CrossRefPubMed
28.
Zurück zum Zitat The Cancer Genome Atlas Research Network, Kandoth C, Schultz N et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73CrossRefPubMedCentral The Cancer Genome Atlas Research Network, Kandoth C, Schultz N et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73CrossRefPubMedCentral
29.
Zurück zum Zitat Djordjevic B, Barkoh BA, Luthra R, Broaddus RR (2013) Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol 26:1401–1412CrossRefPubMedPubMedCentral Djordjevic B, Barkoh BA, Luthra R, Broaddus RR (2013) Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol 26:1401–1412CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Rodolakis A, Thomakos N, Akrivos N et al (2012) Clinicopathologic insight of simultaneously detected primary endometrial and ovarian carcinomas. Arch Gynecol Obstet 285:817–821CrossRefPubMed Rodolakis A, Thomakos N, Akrivos N et al (2012) Clinicopathologic insight of simultaneously detected primary endometrial and ovarian carcinomas. Arch Gynecol Obstet 285:817–821CrossRefPubMed
31.
Zurück zum Zitat Uccella S, Cha SS, Melton LJ 3rd et al (2011) Risk factors for developing multiple malignancies in patients with endometrial cancer. Int J Gynecol Cancer 21:896–901CrossRefPubMedPubMedCentral Uccella S, Cha SS, Melton LJ 3rd et al (2011) Risk factors for developing multiple malignancies in patients with endometrial cancer. Int J Gynecol Cancer 21:896–901CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Williams MG, Bandera EV, Demissie K, Rodriguez-Rodriguez L (2009) Synchronous primary ovarian and endometrial cancers: a population-based assessment of survival. Obstet Gynecol 113:783–789CrossRefPubMed Williams MG, Bandera EV, Demissie K, Rodriguez-Rodriguez L (2009) Synchronous primary ovarian and endometrial cancers: a population-based assessment of survival. Obstet Gynecol 113:783–789CrossRefPubMed
Metadaten
Titel
Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles
verfasst von
Linda E. Kelemen
Peter F. Rambau
Jennifer M. Koziak
Helen Steed
Martin Köbel
Publikationsdatum
13.02.2017
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 5/2017
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0855-5

Weitere Artikel der Ausgabe 5/2017

Cancer Causes & Control 5/2017 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.